A dominant negative inhibitor indicates that monocyte chemoattractant protein 1 functions as a dimer.
about
Structural rearrangement of human lymphotactin, a C chemokine, under physiological solution conditionsIdentification of oligopeptide sequences which inhibit migration induced by a wide range of chemokinesIdentification of amino acid residues critical for aggregation of human CC chemokines macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, and RANTES. Characterization of active disaggregated chemokine variantsThe solution structure of the anti-HIV chemokine vMIP-IICCR2 and CCR5 receptor-binding properties of herpesvirus-8 vMIP-II based on sequence analysis and its solution structureThe structure of MCP-1 in two crystal forms provides a rare example of variable quaternary interactionsAge-associated pro-inflammatory remodeling and functional phenotype in the heart and large arteriesIdentification of human macrophage inflammatory proteins 1alpha and 1beta as a native secreted heterodimerMultimerization of monocyte chemoattractant protein-1 is not required for glycosaminoglycan-dependent transendothelial chemotaxisChronic matrix metalloproteinase inhibition retards age-associated arterial proinflammation and increase in blood pressureMCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesityMutant MCP-1 protein delivery from layer-by-layer coatings on orthopedic implants to modulate inflammatory response.Mutant monocyte chemoattractant protein 1 protein attenuates migration of and inflammatory cytokine release by macrophages exposed to orthopedic implant wear particles.Chemokine receptor oligomerization and allostery.Molecular determinants for CC-chemokine recognition by a poxvirus CC-chemokine inhibitorMapping of MCP-1 functional domains by peptide analysis and site-directed mutagenesis.Role of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks.The C terminus of mouse monocyte chemoattractant protein 1 (MCP1) mediates MCP1 dimerization while blocking its chemotactic potency.Novel process of intrathymic tumor-immune tolerance through CCR2-mediated recruitment of Sirpα+ dendritic cells: a murine model.Proteomic analysis of aorta and protective effects of grape seed procyanidin B2 in db/db mice reveal a critical role of milk fat globule epidermal growth factor-8 in diabetic arterial damageMouse MCP1 C-terminus inhibits human MCP1-induced chemotaxis and BBB compromiseThe CC chemokine ligand, CCL2/MCP1, participates in macrophage fusion and foreign body giant cell formation.Anti-monocyte chemoattractant protein 1 gene therapy attenuates experimental chronic pancreatitis induced by dibutyltin dichloride in rats.Design and receptor interactions of obligate dimeric mutant of chemokine monocyte chemoattractant protein-1 (MCP-1).Renaming cytokines: MCP-1, major chemokine in pancreatitisGene therapy for the prevention of vein graft diseaseLocal delivery of mutant CCL2 protein-reduced orthopaedic implant wear particle-induced osteolysis and inflammation in vivoPrenatal fat-rich diet exposure alters responses of embryonic neurons to the chemokine, CCL2, in the hypothalamus.An engineered monomer of CCL2 has anti-inflammatory properties emphasizing the importance of oligomerization for chemokine activity in vivo.Chemerin reveals its chimeric natureDependence of monocyte chemoattractant protein 1 induced hyperalgesia on the isolectin B4-binding protein versican.AAV1/2-mediated CNS gene delivery of dominant-negative CCL2 mutant suppresses gliosis, beta-amyloidosis, and learning impairment of APP/PS1 mice.Milk fat globule protein epidermal growth factor-8: a pivotal relay element within the angiotensin II and monocyte chemoattractant protein-1 signaling cascade mediating vascular smooth muscle cells invasion.Chemerin is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells.Monocyte chemoattractant protein-1 (MCP-1): an overviewX-ray structure analysis of a designed oligomeric miniprotein reveals a discrete quaternary architecture.Chemotactic cytokines, obesity and type 2 diabetes: in vivo and in vitro evidence for a possible causal correlation?Role of chemokine CCL2 and its receptor CCR2 in neurodegenerative diseases.Monocyte chemoattractant protein-1 and the blood-brain barrier.Chemokines and their receptors in intracerebral hemorrhage.
P2860
Q24292437-C7A49192-72F0-4B56-9738-17912B38E4EAQ24531525-16B0562F-2330-44B8-9D76-E323EF316EF7Q27618367-39D967B9-6C13-4B47-9502-39D3FF750A13Q27620649-19B0DC81-851B-4682-AE52-2F28144DBC79Q27631819-F204BFE1-A224-4A18-B283-1995E3F9FF27Q27734322-E33B39C8-296D-4850-ACC6-8D1A15D04F0AQ28080582-8B7E50B6-D123-4962-AF70-57B6D1BFFFE2Q28207703-838FF52B-F1A6-41E3-A039-AFDA7EFE7E79Q28349180-59FF6191-BAD2-47EF-A901-B51DDD0938ECQ28392730-922F8EB6-17EE-4EC3-9408-6481B050B741Q29614283-D792CDB2-1B46-4182-BEFF-8CDE70923FCCQ33598951-E74773A7-793D-4A4B-BF6E-33E07946EA71Q33671394-16CBDBF9-ED92-4B78-90E8-B73E84DFB704Q33810517-843329B3-2EDD-4968-8ADC-F2FEFEE1A7C4Q33929458-D08B4FC8-85D0-41DB-917F-A2EEC58487E9Q34067117-7A953336-E09E-4684-A224-9E15F35DE4ECQ34170906-BE046606-433D-4B8F-B878-E81F33B19223Q34181442-B5A009D3-3F9C-4AA7-A90E-AA87DE49A1F5Q34345734-E9199409-342A-409C-8B40-1575943ABBB8Q34534094-ADE89DE6-E359-47A8-BD75-8A6F367C7954Q35085550-83E78F58-1CF9-4BD5-8C8D-1E62C89D6934Q35103605-A2091DC5-6618-49E2-9104-2C52A8BF384DQ35597994-51D525A6-2A2D-4BBD-AC5F-7FB349C193C3Q35922575-96D9F82F-5FCD-4559-957E-80D7E6596868Q36164454-709BB904-80AE-4C39-851D-72FE18A01416Q36698258-B453D305-CF49-4E50-881A-F52A7FB50E85Q36756957-4A385034-9694-40E2-BA1B-F54FC0F75AB2Q36818315-09998605-C598-475D-9DDA-005BF5CE7144Q36882279-0C0B058F-84DF-4563-A99E-E5ABF79EFF60Q36916411-49300EDF-CCBA-40C8-9A50-63325265C11AQ37198842-07BDDA81-3F9A-4064-9DCA-6FA15FBB6E88Q37260178-96487FFC-8F48-43CA-A830-9A463EEDB70DQ37394615-74D5C209-94EA-42B4-95A8-E7EC7FDA0B4BQ37429204-71B31A36-0C16-45CC-81C7-BBD7191EB0FCQ37481208-20F44030-01B3-459D-98DD-E20E12731E13Q37484542-821F673D-C0BA-4E92-AAE8-5DAA3A802F2EQ37583987-A29C2BD5-12A4-4433-8DF6-BA24A9B66F8CQ38114832-0959B829-A8C7-4810-9587-98C7885DEAC6Q38139823-A19FA2F1-868D-4C70-97EA-A0880F3D8ABCQ38170067-254037AE-4396-443D-94AA-D82DE7A9268E
P2860
A dominant negative inhibitor indicates that monocyte chemoattractant protein 1 functions as a dimer.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
A dominant negative inhibitor ...... rotein 1 functions as a dimer.
@ast
A dominant negative inhibitor ...... rotein 1 functions as a dimer.
@en
type
label
A dominant negative inhibitor ...... rotein 1 functions as a dimer.
@ast
A dominant negative inhibitor ...... rotein 1 functions as a dimer.
@en
prefLabel
A dominant negative inhibitor ...... rotein 1 functions as a dimer.
@ast
A dominant negative inhibitor ...... rotein 1 functions as a dimer.
@en
P2860
P356
P1476
A dominant negative inhibitor ...... rotein 1 functions as a dimer.
@en
P2093
P2860
P304
P356
10.1128/MCB.15.9.4851
P407
P577
1995-09-01T00:00:00Z